However, there are certain front line benefits of canertinib and afatinib (irreversible TKI), which makes it a far superior agent than EGFR specific reversible TKI erlotinib in pancreatic cancer therapy. This evidence concerns the gene EGFR and familial pancreatic carcinoma.